KYNTRA BIO, INC. (KYNB)

Every figure this model derived for KYNB, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 9,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 91,318,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 96,825,000 AssetsCurrent 2026-06-30
current liabilities 36,040,000 LiabilitiesCurrent 2026-06-30
equity -30,144,000 StockholdersEquity 2026-06-30
interest expense 9,291,000 InterestExpense 2026-06-30
ocf -4,774,000 NetCashProvidedByUsedInOperatingActivities 2025-12-31
revenue 4,617,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 3,986,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up KYNB on one particular measure came for.

RatioValue
cash operating margin-999.48
current ratio3.16
current ratio reported2.69
deferred revenue growth-80.16
dilution pct1.03
fcf margin-103.6
interest cover-5.42
operating margin-1089.78
owner earnings margin-189.93
revenue growth-37.14
revenue growth per share-37.78
rule of 40-1126.92
sbc pct revenue86.33

What to be careful about

What this model itself distrusts about KYNB's figures. Written by the derivation as it ran, not added afterwards.